Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Silvio Inzucchi MD
Silvio E. Inzucchi MD Editor-in-Chief
Richard Pratley MD
Richard E. Pratley MD Associate Editor
Deborah Wexler MD, MSc
Deborah J. Wexler MD, MSc Associate Editor
See All Experts
Published in Diabetes

Journal Scan / Research · September 23, 2023

Impact of Tirzepatide on 10-Year Predicted Risk of Developing Type 2 Diabetes in Patients With Overweight or Obesity

Diabetes, Obesity & Metabolism

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Carolina Gonzalez-Lopez MD

Diabetes, Obesity & Metabolism
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial
Diabetes Obes Metab 2023 Sep 12;[EPub Ahead of Print], ER Hankosky, H Wang, LM Neff, H Kan, F Wang, NN Ahmad, A Stefanski, WT Garvey

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated